David Zaccardelli - Oct 7, 2025 Form 4 Insider Report for Verona Pharma plc (VRNA)

Signature
/s/ Andrew Fisher, Attorney-in-fact for David Zaccardelli
Stock symbol
VRNA
Transactions as of
Oct 7, 2025
Transactions value $
$0
Form type
4
Date filed
10/8/2025, 04:44 PM
Previous filing
Sep 3, 2025

Reporting Owners (1)

Name Relationship Address Signature Signature date CIK
ZACCARDELLI DAVID President and CEO, Director 3 MORE LONDON RIVERSIDE, LONDON, UNITED KINGDOM /s/ Andrew Fisher, Attorney-in-fact for David Zaccardelli 2025-10-08 0001627642

Transactions Table

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Ownership Footnotes
transaction VRNA Ordinary Shares Disposed to Issuer -12.2M -100% 0 Oct 7, 2025 Direct F1, F2, F3, F4
transaction VRNA Ordinary Shares Options Exercise +3.29M 3.29M Oct 7, 2025 Direct F1, F4, F6
transaction VRNA Ordinary Shares Disposed to Issuer -3.29M -100% 0 Oct 7, 2025 Direct F1, F4, F6

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
transaction VRNA Restricted Share Unit Options Exercise -800K -100% 0 Oct 7, 2025 Ordinary Shares 800K Direct F1, F4, F5, F6
transaction VRNA Restricted Share Unit Options Exercise -390K -100% 0 Oct 7, 2025 Ordinary Shares 390K Direct F1, F4, F5
transaction VRNA Restricted Share Unit Options Exercise -446K -100% 0 Oct 7, 2025 Ordinary Shares 446K Direct F1, F4, F5
transaction VRNA Restricted Share Unit Award +1.65M 1.65M Oct 7, 2025 Ordinary Shares 1.65M Direct F1, F5, F6
transaction VRNA Restricted Share Unit Options Exercise -1.65M -100% 0 Oct 7, 2025 Ordinary Shares 1.65M Direct F1, F5, F6
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

David Zaccardelli is no longer subject to Section 16 filing requirements. Form 4 or Form 5 obligations may continue.

Explanation of Responses:

Id Content
F1 Reported securities are represented by American Depositary Shares ("ADSs"), each of which represents eight (8) Ordinary Shares of the Issuer.
F2 Represents Ordinary Shares of the Issuer acquired from the Reporting Person by means of a scheme of arrangement (the "Scheme of Arrangement") under Part 26 of the UK Companies Act 2006, pursuant to a transaction agreement, dated as of July 8, 2025 (the "Transaction Agreement"), by and among the Issuer, Merck Sharp & Dohme LLC, a New Jersey limited liability company ("Parent") and Vol Holdings LLC, a Delaware limited liability company and wholly owned subsidiary of Parent ("Bidco").
F3 At the effective time of the Scheme of Arrangement (the "Effective Time"), each holder of the Scheme Shares (as defined in the Scheme of Arrangement) became entitled to receive $13.375 in cash per Scheme Share, without interest and net of any applicable withholding taxes. Because each ADS represents a beneficial ownership interest in eight (8) Ordinary Shares of the Issuer, holders of ADSs as of the Effective Time became entitled to receive eight (8) times the foregoing cash amount, or $107 in cash, without interest and net of any applicable withholding taxes, per ADS (the "ADS Consideration").
F4 Pursuant to the terms of the Transaction Agreement, immediately prior to the Effective Time, each outstanding time-based restricted share unit award ("RSU Award"), unless agreed otherwise, became fully vested, and at the Effective Time, was automatically converted into the right to receive an amount in cash (without interest and subject to all required withholding taxes) equal to the product of (i) the aggregate number of ADSs underlying such RSU Award and (ii) the ADS Consideration.
F5 Represents an award of RSUs covering ADSs, which is presented in terms of the equivalent number of Ordinary Shares underlying the ADSs. Each RSU represents a contingent right to receive one (1) ADS of the Issuer. Each ADS represents eight (8) Ordinary Shares of the Issuer. The RSUs have no expiration date.
F6 These performance-based restricted share unit awards (the "PRSUs") were earned upon the determination by the Board of Directors of the Issuer that certain performance metrics had been achieved. Pursuant to the terms of the Transaction Agreement, immediately prior to the Effective Time, the PRSUs, unless agreed otherwise, became fully vested, and at the Effective Time, were automatically converted into the right to receive an amount in cash (without interest and subject to all required withholding taxes) equal to the product of (i) the aggregate number of ADSs underlying such PRSU Award and (ii) the ADS Consideration.